BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 26462931)

  • 1. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy.
    Suer E; Hamidi N; Gokce MI; Gulpinar O; Turkolmez K; Beduk Y; Baltaci S
    World J Urol; 2016 Jun; 34(6):847-51. PubMed ID: 26462931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of repeat radical transurethral resection for selected patients with muscle-invasive bladder cancer.
    Li Z; Li Y; Lu Q; Chen J
    ANZ J Surg; 2018 Oct; 88(10):1033-1036. PubMed ID: 29974604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
    Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Radical cystectomy in the treatment of bladder cancer always in due time?].
    May M; Braun KP; Richter W; Helke C; Vogler H; Hoschke B; Siegsmund M
    Urologe A; 2007 Aug; 46(8):913-9. PubMed ID: 17676301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome.
    Herr HW
    J Clin Oncol; 2001 Jan; 19(1):89-93. PubMed ID: 11134199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study.
    Kamiya N; Suzuki H; Suyama T; Kobayashi M; Fukasawa S; Sekita N; Mikami K; Nihei N; Naya Y; Ichikawa T
    Int J Clin Oncol; 2017 Apr; 22(2):353-358. PubMed ID: 27744487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
    Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
    BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
    Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
    BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
    J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial.
    Eroglu A; Ekin RG; Koc G; Divrik RT
    Int J Clin Oncol; 2020 Apr; 25(4):698-704. PubMed ID: 31760524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organ-sparing treatment in muscle-invasive bladder cancer.
    Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
    Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining DWI radiomics features with transurethral resection promotes the differentiation between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer.
    Xu S; Yao Q; Liu G; Jin D; Chen H; Xu J; Li Z; Wu G
    Eur Radiol; 2020 Mar; 30(3):1804-1812. PubMed ID: 31773297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer.
    Sauer R; Birkenhake S; Kühn R; Wittekind C; Schrott KM; Martus P
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):121-7. PubMed ID: 9422567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder sparing surgery in high-grade bladder cancer.
    Yakovlev PG; Klyushin DA; Vereshchako RI
    Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
    Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
    Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
    Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
    BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Narrow-band imaging (NBI) and white light (WLI) transurethral resection of the bladder in the treatment of non-muscle-invasive bladder cancer.
    Montanari E; de la Rosette J; Longo F; Del Nero A; Laguna P
    Arch Ital Urol Androl; 2012 Dec; 84(4):179-83. PubMed ID: 23427740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.